Neuphoria Therapeutics Inc(NEUP)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NEUP Neuphoria Therapeutics Inc

交易中 10-09 13:40:16 EDT

3.35

+0.00

+0.01%

最高3.41	最低3.32	成交量2,168
今开3.33	昨收3.35	日振幅2.68%
总市值1,811万	流通市值1,800万	总股本540.46万
成交额7,250	换手率0.04%	流通股本537.20万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NEUP","market":"US","secType":"STK","nameCN":"Neuphoria Therapeutics Inc","latestPrice":3.3504,"timestamp":1791565877084,"preClose":3.35,"halted":0,"volume":2168,"delay":0,"changeRate":0.00011940298507461371,"floatShares":5371970,"shares":5404551,"eps":-3.060194,"marketStatus":"交易中","change":0.0004,"latestTime":"10-09 13:40:16 EDT","open":3.33,"high":3.41,"low":3.3201,"amount":7249.555688,"amplitude":0.026836,"askPrice":3.5,"askSize":115,"bidPrice":3.36,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":-3.060194,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1791576000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":3.35,"preHourTrading":{"tag":"盘前","latestPrice":3.33,"preClose":3.35,"latestTime":"08:10 EDT","volume":10,"amount":33.3,"timestamp":1791547825154,"change":-0.02,"changeRate":-0.00597,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":3.35,"preClose":3.35,"latestTime":"16:10 EDT","volume":14,"amount":46.9,"timestamp":1791490204349,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.257106},"requestUrl":"/m/hq/s/NEUP","defaultTab":"news","newsList":[{"id":"1176904367","title":"Neuphoria Therapeutics 盘后交易量清淡中股价上涨6%至4.85美元，确认与Scancell就潜在收购进行谈判","url":"https://stock-news.laohu8.com/highlight/detail?id=1176904367","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176904367?lang=zh_cn&edition=full","pubTime":"2026-06-27 04:41","pubTimestamp":1782506475,"startTime":"0","endTime":"0","summary":"Neuphoria Therapeutics Inc 的股价在盘后交易时段录得显著上涨，涨幅达到6%，最终报收于4.85美元。值得注意的是，此次上涨是在交易量相对清淡的背景下发生的。与此同时，该公司正式确认，目前正与生物制药公司Scancell就一项潜在的收购交易进行谈判。这一消息的公布，为股价在非主要交易时段的波动提供了直接的市场解释。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEUP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131682355","title":"Neuphoria Therapeutics确认与Scancell就潜在收购进行谈判，后者有望登陆纳斯达克","url":"https://stock-news.laohu8.com/highlight/detail?id=1131682355","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131682355?lang=zh_cn&edition=full","pubTime":"2026-06-27 04:29","pubTimestamp":1782505754,"startTime":"0","endTime":"0","summary":"Neuphoria Therapeutics Inc已确认，公司正与Scancell就一项潜在的收购交易进行讨论。若交易达成，Scancell将借此机会实现在纳斯达克市场的上市。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NEUP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neuphoriatx.com","stockEarnings":[{"period":"1week","weight":-0.0456},{"period":"1month","weight":-0.1067},{"period":"3month","weight":-0.0537},{"period":"6month","weight":-0.2992},{"period":"1year","weight":-0.8176},{"period":"ytd","weight":-0.1366}],"compareEarnings":[{"period":"1week","weight":0.013},{"period":"1month","weight":0.0104},{"period":"3month","weight":0.0251},{"period":"6month","weight":0.139},{"period":"1year","weight":0.1498},{"period":"ytd","weight":0.1349}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Neuphoria Therapeutics Inc.（原名Bionomics Limited）于1996年根据澳大利亚法律注册成立，并于2024年12月24日迁移至特拉华州并成为美国公司。作为一家临床阶段的生物技术公司，它开发神经精神障碍疗法。其主要候选药物BNC210（口服选择性α 7烟碱性ACH受体调节剂）针对急性SAD和慢性PTSD，超过2700万美国患者的需求未得到满足。BNC210是一种首创的抗焦虑疗法，可在没有镇静、认知问题或成瘾的情况下快速恢复神经递质平衡。它与默沙东（美国/加拿大以外）就两种早期临床CNS药物建立了合作伙伴关系。其管线包括下一代α 7受体和KV3.1/3.2临床前项目（先导优化）。目前的治疗方法（抗抑郁药、苯二氮卓类药物）几十年来缺乏FDA的新批准，存在缺陷；BNC210在试验中显示出快速的作用和没有限制性副作用。","exchange":"NASDAQ","name":"Neuphoria Therapeutics Inc","nameEN":"Neuphoria Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Neuphoria Therapeutics Inc(NEUP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Neuphoria Therapeutics Inc(NEUP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Neuphoria Therapeutics Inc,NEUP,Neuphoria Therapeutics Inc股票,Neuphoria Therapeutics Inc股票老虎,Neuphoria Therapeutics Inc股票老虎国际,Neuphoria Therapeutics Inc行情,Neuphoria Therapeutics Inc股票行情,Neuphoria Therapeutics Inc股价,Neuphoria Therapeutics Inc股市,Neuphoria Therapeutics Inc股票价格,Neuphoria Therapeutics Inc股票交易,Neuphoria Therapeutics Inc股票购买,Neuphoria Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Neuphoria Therapeutics Inc(NEUP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Neuphoria Therapeutics Inc(NEUP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}